Contact
searchSearch
HMP Global
Conference Coverage
Black Women More Likely to Experience Dose Delays, Worse Outcomes in Triple-Negative Breast Cancer Treatment
06/10/2022
Findings presented at the 2022 ASCO Annual Meeting suggest there are disparities in care for Black women with triple-negative breast cancer as compared with White women.
Findings presented at the 2022 ASCO Annual Meeting suggest there are disparities in care for Black women with triple-negative breast cancer as compared with White women.
Findings presented at the 2022...
06/10/2022
First Report Managed Care
Conference Coverage
Symptom-Related Quality of Life in Patients Treated With First-Line Ribociclib vs Ademaciclib
06/10/2022
Investigators at the 2022 ASCO Annual Meeting compared symptoms in patients receiving either ribociclib or abemaciclib in combination with endocrine therapy in the front-line setting for HR+/HER2- advanced breast cancer.
Investigators at the 2022 ASCO Annual Meeting compared symptoms in patients receiving either ribociclib or abemaciclib in combination with endocrine therapy in the front-line setting for HR+/HER2- advanced breast cancer.
Investigators at the 2022 ASCO...
06/10/2022
First Report Managed Care
Conference Coverage
Treatment Costs, Care of Patients With Metastatic Breast Cancer in the United States
06/10/2022
Costs related to metastatic breast cancer vary by receptor subtype as well as the number of years postdiagnosis, according to research presented at the 2022 ASCO Annual Meeting.
Costs related to metastatic breast cancer vary by receptor subtype as well as the number of years postdiagnosis, according to research presented at the 2022 ASCO Annual Meeting.
Costs related to metastatic...
06/10/2022
First Report Managed Care
Conference Coverage
Coverage-Related Survival Disparities in Patients With Waldenström Macroglobulinemia
06/09/2022
Presenters at the 2022 ASCO Annual Meeting studied whether insurance status and type impacted overall survival rates among patients with Waldenström Macroglobulinemia.
Presenters at the 2022 ASCO Annual Meeting studied whether insurance status and type impacted overall survival rates among patients with Waldenström Macroglobulinemia.
Presenters at the 2022 ASCO...
06/09/2022
First Report Managed Care
Conference Coverage
Research Underfunded for Cancers With High Mortality, Incidence Among Black Patients
06/08/2022
"Underfunding strongly correlates with fewer clinical trials, which could impede future advances in underfunded cancers," wrote investigators from the 2022 ASCO Annual Meeting.
"Underfunding strongly correlates with fewer clinical trials, which could impede future advances in underfunded cancers," wrote investigators from the 2022 ASCO Annual Meeting.
"Underfunding strongly...
06/08/2022
First Report Managed Care
Conference Coverage
Assessing Alpelisib, Fulvestrant Benefit Among Patients With Advanced Breast Cancer
06/07/2022
“Clinical benefit was maintained regardless of alterations in most biomarkers, including ESR1 and genes implicated in CDK4/6i resistance, consistent with alpelisib targeting the PIK3CA driver oncogene,” wrote researchers.
“Clinical benefit was maintained regardless of alterations in most biomarkers, including ESR1 and genes implicated in CDK4/6i resistance, consistent with alpelisib targeting the PIK3CA driver oncogene,” wrote researchers.
“Clinical benefit was maintained...
06/07/2022
First Report Managed Care
Conference Coverage
Real-World Data Suggests Palbociclib Efficacious for Treating HR+/HER2- Advanced Breast Cancer
06/06/2022
A multicenter study of real-world practices in China showed palbociclib plus endocrine therapy was efficacious among patients with HR+/HER2- advanced breast cancer.
A multicenter study of real-world practices in China showed palbociclib plus endocrine therapy was efficacious among patients with HR+/HER2- advanced breast cancer.
A multicenter study of...
06/06/2022
First Report Managed Care
Conference Coverage
Effect of Ribociclib Dose Modifications on Overall Survival in Patients With HR+/HER2- Advanced Breast Cancer
06/06/2022
Researchers at the 2022 ASCO Annual Meeting shared promising results from a trial examining the effect of dosage modifications on overall survival among postmenopausal patients with HR+/HER2- advanced breast cancer.
Researchers at the 2022 ASCO Annual Meeting shared promising results from a trial examining the effect of dosage modifications on overall survival among postmenopausal patients with HR+/HER2- advanced breast cancer.
Researchers at the 2022 ASCO...
06/06/2022
First Report Managed Care

Experts in oncology come together to debate current controversies and share new research and innovation aimed at improving patient care, outcomes, and health equity. 

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use